GSK's regulatory filing for expanded use of RSV vaccine, Arexvy, in adults aged 18 years and older has been accepted for ...

GSK has applied to the European Medicines Agency to expand use of its respiratory syncytial virus (RSV) vaccine to adults ...

London: GSK plc has announced that the European Medicines Agency (EMA) has accepted the company's regulatory application to ...

Sales of the vaccine have been declining due to weak demand trends in China amid an economic slowdown. Gardasil sales ...

GSK plc GSK announced that the European Medicines Agency (EMA) has accepted the regulatory application seeking approval to expand the use of its adjuvanted recombinant respiratory syncytial virus ...

Pfizer's RSV shot Abrysvo was cleared by the FDA last October for the 18 to 59 age group, extending its 2023 approval in the ...

The EMA’s acceptance of the application to extend the use of Arexvy represents a significant step in broadening the vaccine’s reach to a wider adult population. Arexvy was the first RSV ...

GSK GSK stock has risen 21.5% in the past six months. The consistently strong performance of the Specialty Medicines unit, ...

EMA accepts for regulatory review GSK’s RSV vaccine, Arexvy to expand use in adults 18 years and older: London, UK Saturday, June 14, 2025, 10:00 Hrs [IST] GSK plc announced tha ...

Dublin, May 29, 2025 (GLOBE NEWSWIRE) -- The "Abrysvo or Arexvy Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" report has been added to ResearchAndMarkets.com's ...

Arexvy was the first RSV vaccine approved in the European Economic Area for the prevention of lower respiratory tract disease caused by RSV in adults aged 60 and older, and for those aged 50 to 59 ...